NO312009B1 - Anvendelse av et konjugat av en målsökende gruppe og 213BBi radioisotop for fremstilling av et medikament - Google Patents
Anvendelse av et konjugat av en målsökende gruppe og 213BBi radioisotop for fremstilling av et medikament Download PDFInfo
- Publication number
- NO312009B1 NO312009B1 NO19932687A NO932687A NO312009B1 NO 312009 B1 NO312009 B1 NO 312009B1 NO 19932687 A NO19932687 A NO 19932687A NO 932687 A NO932687 A NO 932687A NO 312009 B1 NO312009 B1 NO 312009B1
- Authority
- NO
- Norway
- Prior art keywords
- isotope
- dose
- targeting group
- radioisotope
- targeting
- Prior art date
Links
- 230000008685 targeting Effects 0.000 title claims description 37
- 239000003814 drug Substances 0.000 title claims description 5
- 229940079593 drug Drugs 0.000 title claims description 5
- 238000004519 manufacturing process Methods 0.000 claims abstract description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 5
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 abstract description 13
- 238000000034 method Methods 0.000 abstract description 8
- 238000011363 radioimmunotherapy Methods 0.000 abstract description 4
- 230000002285 radioactive effect Effects 0.000 abstract description 3
- 238000001959 radiotherapy Methods 0.000 abstract description 2
- 229940051022 radioimmunoconjugate Drugs 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 35
- 230000004083 survival effect Effects 0.000 description 15
- 239000002245 particle Substances 0.000 description 14
- 239000003480 eluent Substances 0.000 description 12
- 238000010828 elution Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 8
- 239000003978 infusion fluid Substances 0.000 description 8
- 238000005342 ion exchange Methods 0.000 description 8
- 239000002243 precursor Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 231100000433 cytotoxic Toxicity 0.000 description 7
- 230000001472 cytotoxic effect Effects 0.000 description 7
- 230000005855 radiation Effects 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 230000004992 fission Effects 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 239000002738 chelating agent Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
- 229910052797 bismuth Inorganic materials 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 229910017604 nitric acid Inorganic materials 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 2
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229910052767 actinium Inorganic materials 0.000 description 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 2
- 230000005258 radioactive decay Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- OOIBFPKQHULHSQ-UHFFFAOYSA-N (3-hydroxy-1-adamantyl) 2-methylprop-2-enoate Chemical compound C1C(C2)CC3CC2(O)CC1(OC(=O)C(=C)C)C3 OOIBFPKQHULHSQ-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100021472 Equilibrative nucleoside transporter 3 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000822041 Homo sapiens Equilibrative nucleoside transporter 3 Proteins 0.000 description 1
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 1
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- ZMPZNCDIFIQVJZ-UHFFFAOYSA-N acetic acid;n'-[2-(cyclohexylamino)ethyl]ethane-1,2-diamine Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.NCCNCCNC1CCCCC1 ZMPZNCDIFIQVJZ-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229910052768 actinide Inorganic materials 0.000 description 1
- 150000001255 actinides Chemical class 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- LBDSXVIYZYSRII-IGMARMGPSA-N alpha-particle Chemical compound [4He+2] LBDSXVIYZYSRII-IGMARMGPSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004882 non-tumor cell Anatomy 0.000 description 1
- 239000003758 nuclear fuel Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 239000002901 radioactive waste Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 231100000628 reference dose Toxicity 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- G—PHYSICS
- G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
- G21G—CONVERSION OF CHEMICAL ELEMENTS; RADIOACTIVE SOURCES
- G21G4/00—Radioactive sources
- G21G4/04—Radioactive sources other than neutron sources
- G21G4/06—Radioactive sources other than neutron sources characterised by constructional features
- G21G4/08—Radioactive sources other than neutron sources characterised by constructional features specially adapted for medical application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Optics & Photonics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Dispersion Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Engineering & Computer Science (AREA)
- High Energy & Nuclear Physics (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Electrotherapy Devices (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fats And Perfumes (AREA)
- Compounds Of Unknown Constitution (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Massaging Devices (AREA)
- Tents Or Canopies (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP92202301 | 1992-07-27 | ||
| EP93200388 | 1993-02-11 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO932687D0 NO932687D0 (no) | 1993-07-26 |
| NO932687L NO932687L (no) | 1994-01-28 |
| NO312009B1 true NO312009B1 (no) | 2002-03-04 |
Family
ID=26131590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19932687A NO312009B1 (no) | 1992-07-27 | 1993-07-26 | Anvendelse av et konjugat av en målsökende gruppe og 213BBi radioisotop for fremstilling av et medikament |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US5641471C1 (de) |
| EP (1) | EP0585986B1 (de) |
| JP (1) | JP3959431B2 (de) |
| KR (1) | KR100304155B1 (de) |
| AT (1) | ATE206622T1 (de) |
| AU (1) | AU676162B2 (de) |
| CA (1) | CA2100709C (de) |
| DE (1) | DE69330899T2 (de) |
| DK (1) | DK0585986T3 (de) |
| ES (1) | ES2165361T3 (de) |
| FI (1) | FI118676B (de) |
| MX (1) | MX9304499A (de) |
| NO (1) | NO312009B1 (de) |
| NZ (1) | NZ248235A (de) |
| PT (1) | PT585986E (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6403771B1 (en) | 1991-02-19 | 2002-06-11 | Actinium Pharmaceuticals, Limited | Method and means for site directed therapy |
| CA2100709C (en) * | 1992-07-27 | 2004-03-16 | Maurits W. Geerlings | Method and means for site directed therapy |
| ES2183904T3 (es) * | 1996-11-15 | 2003-04-01 | Euratom | Metodo extracorporeo para el tratamiento de celulas sanguineas. |
| US5749042A (en) * | 1997-01-28 | 1998-05-05 | Battelle Memorial Institute | Bismuth generator method |
| US5854968A (en) * | 1997-06-09 | 1998-12-29 | Arch Development Corporation | Process and apparatus for the production of BI-213 cations |
| US6603127B1 (en) * | 1998-03-30 | 2003-08-05 | Sloan-Kettering Institute For Cancer Research | Bismuth-213 generator and uses thereof |
| US7736651B1 (en) | 2000-11-24 | 2010-06-15 | Sloan-Kettering Institute For Cancer Research | Alpha emitting constructs and uses thereof |
| ATE381345T1 (de) * | 1998-05-26 | 2008-01-15 | Sloan Kettering Inst Cancer | Alpha-emittierende konstrukte sowie deren verwendung |
| ATE246395T1 (de) | 1998-06-22 | 2003-08-15 | Europ Economic Community | Verfahren und vorrichtung zur erzeugung von bi- 213 für menschliche therapeutische verwendung |
| JP2004510683A (ja) * | 1999-06-07 | 2004-04-08 | センター・フォー・モレキュラー・メディシン・アンド・イムノロジー | 放射免疫療法において断片に付着されるα線エミッタまたはβ線エミッタ |
| US6852296B2 (en) * | 2001-06-22 | 2005-02-08 | Pg Research Foundation | Production of ultrapure bismuth-213 for use in therapeutic nuclear medicine |
| US7087206B2 (en) * | 2002-04-12 | 2006-08-08 | Pg Research Foundation | Multicolumn selectivity inversion generator for production of high purity actinium for use in therapeutic nuclear medicine |
| WO2004001767A1 (en) * | 2002-06-21 | 2003-12-31 | Lynntech, Inc. | Ion exchange materials for use in a bi-213 generator |
| EP1479399A1 (de) * | 2003-05-22 | 2004-11-24 | European Atomic Energy Community (Euratom) | Verfahren zum Beladen eines Radioelementerzeugers mit einem Mutternuklid |
| US20050105666A1 (en) * | 2003-09-15 | 2005-05-19 | Saed Mirzadeh | Production of thorium-229 |
| CA2768658C (en) | 2009-07-22 | 2018-04-03 | Actinium Pharmaceuticals, Inc. | Methods for generating radioimmunoconjugates |
| EP3302560A4 (de) | 2015-06-05 | 2019-01-09 | Panacea Pharmaceuticals, Inc. | Radiobildgebung und radiotherapie von krebs unter verwendung von antikörpern gegen haah |
| EP3409297A1 (de) | 2017-05-30 | 2018-12-05 | AlfaRim Medial Holding B.V. | Optimaler 225actinium-213bismut-generator für alpha-partikelradioimmunotherapie |
| WO2019057598A1 (en) | 2017-09-20 | 2019-03-28 | Alfarim Medical Holding B.V. | OPTIMAL 225ACTINIUM - 213BISMUTH GENERATOR FOR ALPHA PARTICLE RADIO IMMUNOTHERAPY |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4001387A (en) * | 1973-07-30 | 1977-01-04 | Medi-Physics, Inc. | Process for preparing radiopharmaceuticals |
| US4305922A (en) * | 1978-10-04 | 1981-12-15 | University Patents, Inc. | Labeling proteins with 99m-Tc by ligand exchange |
| US4296785A (en) * | 1979-07-09 | 1981-10-27 | Mallinckrodt, Inc. | System for generating and containerizing radioisotopes |
| US4454106A (en) * | 1982-06-07 | 1984-06-12 | Gansow Otto A | Use of metal chelate conjugated monoclonal antibodies |
| US4472509A (en) * | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
| CA1225930A (en) * | 1982-06-07 | 1987-08-25 | Otto A. Gansow | Metal chelate conjugated monoclonal antibodies |
| GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4732864A (en) * | 1983-10-06 | 1988-03-22 | E. I. Du Pont De Nemours And Company | Trace-labeled conjugates of metallothionein and target-seeking biologically active molecules |
| US4828991A (en) * | 1984-01-31 | 1989-05-09 | Akzo N.V. | Tumor specific monoclonal antibodies |
| US4663129A (en) * | 1985-01-30 | 1987-05-05 | The United States Of America As Represented By The United States Department Of Energy | Isotopic generator for bismuth-212 and lead-212 from radium |
| AU2068588A (en) * | 1987-08-12 | 1989-02-16 | Immunomedics Inc. | Preparation of radiolabeled conjugates |
| US4833329A (en) * | 1987-11-20 | 1989-05-23 | Mallinckrodt, Inc. | System for generating and containerizing radioisotopes |
| US4871352A (en) * | 1987-12-07 | 1989-10-03 | Controlled Release Technologies, Inc. | Self-regulated therapeutic agent delivery system and method |
| US4923985A (en) * | 1988-05-25 | 1990-05-08 | The United States Of America As Represented By The Department Of Health & Human Services | Process for synthesizing macrocyclic chelates |
| JPH0720989B2 (ja) * | 1988-05-25 | 1995-03-08 | アメリカ合衆国 | 大環状キレート化合物の抱合体と診断的テスト方法 |
| DK0429624T3 (da) * | 1989-06-19 | 1994-05-30 | Akzo Nobel Nv | Radioimmunterapi under anvendelse af alfa-partikelemission |
| EP0484460B1 (de) * | 1989-07-12 | 1996-01-17 | Mallinckrodt Medical, Inc. | Verfahren und Gerät zur Herstellung eines radiodiagnostischen gasförmigen Radionukleids |
| LU87684A1 (de) * | 1990-02-23 | 1991-10-08 | Euratom | Verfahren zur erzeugung von aktinium-225 und wismut-213 |
| US5038046A (en) * | 1990-07-10 | 1991-08-06 | Biotechnetics | Method and generator for producing radioactive lead-212 |
| CA2100709C (en) * | 1992-07-27 | 2004-03-16 | Maurits W. Geerlings | Method and means for site directed therapy |
-
1993
- 1993-07-16 CA CA002100709A patent/CA2100709C/en not_active Expired - Lifetime
- 1993-07-22 DE DE69330899T patent/DE69330899T2/de not_active Expired - Lifetime
- 1993-07-22 AT AT93202174T patent/ATE206622T1/de active
- 1993-07-22 ES ES93202174T patent/ES2165361T3/es not_active Expired - Lifetime
- 1993-07-22 PT PT93202174T patent/PT585986E/pt unknown
- 1993-07-22 EP EP93202174A patent/EP0585986B1/de not_active Expired - Lifetime
- 1993-07-22 DK DK93202174T patent/DK0585986T3/da active
- 1993-07-23 AU AU42154/93A patent/AU676162B2/en not_active Expired
- 1993-07-23 NZ NZ248235A patent/NZ248235A/en not_active IP Right Cessation
- 1993-07-26 MX MX9304499A patent/MX9304499A/es active IP Right Grant
- 1993-07-26 NO NO19932687A patent/NO312009B1/no not_active IP Right Cessation
- 1993-07-26 KR KR1019930014146A patent/KR100304155B1/ko not_active Expired - Lifetime
- 1993-07-26 FI FI933350A patent/FI118676B/fi not_active IP Right Cessation
- 1993-07-27 JP JP18506693A patent/JP3959431B2/ja not_active Expired - Lifetime
-
1995
- 1995-09-12 US US08527296 patent/US5641471C1/en not_active Expired - Lifetime
-
1998
- 1998-01-05 US US09/002,848 patent/US6127527A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| NZ248235A (en) | 1995-04-27 |
| NO932687L (no) | 1994-01-28 |
| AU4215493A (en) | 1994-02-03 |
| KR940005295A (ko) | 1994-03-21 |
| US5641471C1 (en) | 2001-05-15 |
| CA2100709C (en) | 2004-03-16 |
| JPH06157350A (ja) | 1994-06-03 |
| DE69330899D1 (de) | 2001-11-15 |
| MX9304499A (es) | 1994-04-29 |
| AU676162B2 (en) | 1997-03-06 |
| US5641471A (en) | 1997-06-24 |
| JP3959431B2 (ja) | 2007-08-15 |
| KR100304155B1 (ko) | 2001-11-22 |
| FI933350L (fi) | 1994-01-28 |
| EP0585986B1 (de) | 2001-10-10 |
| DE69330899T2 (de) | 2002-04-25 |
| CA2100709A1 (en) | 1994-01-28 |
| EP0585986A1 (de) | 1994-03-09 |
| PT585986E (pt) | 2002-03-28 |
| DK0585986T3 (da) | 2002-01-14 |
| FI933350A0 (fi) | 1993-07-26 |
| ES2165361T3 (es) | 2002-03-16 |
| ATE206622T1 (de) | 2001-10-15 |
| US6127527A (en) | 2000-10-03 |
| FI118676B (fi) | 2008-02-15 |
| NO932687D0 (no) | 1993-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO312009B1 (no) | Anvendelse av et konjugat av en målsökende gruppe og 213BBi radioisotop for fremstilling av et medikament | |
| McDevitt et al. | Preparation of α-emitting 213Bi-labeled antibody constructs for clinical use | |
| US20140235924A1 (en) | Method of radiotherapy | |
| Westrøm et al. | Preparation of 212Pb-labeled monoclonal antibody using a novel 224Ra-based generator solution | |
| AU2005259258B2 (en) | Radionuclides for medical use | |
| US20080279772A1 (en) | Methods for detecting pathological sites | |
| US20060228297A1 (en) | Thorium-227 for use in radiotherapy of soft tissue disease | |
| Larsen et al. | α-Particle radiotherapy with 211At-labeled monodisperse polymer particles, 211At-labeled IgG proteins, and free 211At in a murine intraperitoneal tumor model | |
| RAMLI et al. | Preclinical study of 177Lu-DOTA-trastuzumab: A potential radiopharmaceutical for therapy of breast cancer positive HER-2 | |
| EP1617876B1 (de) | Thorium-227 zur radiotherapie von weichgewebe-erkrankungen | |
| Colcher | Centralized radiolabeling of antibodies for radioimmunotherapy | |
| Dence et al. | Radiochemical synthesis, rodent biodistribution and tumor uptake, and dosimetry calculations of [11 C] methylated LY2181308 | |
| Scheffler et al. | Application of rhenium-188 HEDP in bone metastases therapy | |
| EP0842668B1 (de) | Ex-Corpore Verfahren zur Behändlung von Blut-Zellen | |
| Ünak | Recent advances in medical radionuclide production and future perspective of compact medical cyclotrons | |
| Vaidyanathan et al. | Astatinated radiopharmaceuticals for targeted alpha particle radiotherapy | |
| WO2001054734A2 (en) | 188re-labelled 5-thio-d-glucose for radionucleotide tumor therapy | |
| Nguyen et al. | Study on the Preparation and Quality Control of 131 I-Rituximab and 90 Y-Rituximab and 90 Y-Rituximab for Non-Hodgkin-Lymphoma Therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |